Clinical trial

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate…

NCT00016146 · Memorial Sloan Kettering Cancer Center, Other · Completed

Key facts

NCT number NCT00016146
Title Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer
Official title Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates: A Dose-Escalating Trial Studying The Immunogenicity And Safety Of The Immunological Adjuvant GPI-0100
Lead sponsor Memorial Sloan Kettering Cancer Center, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Prostate Cancer
Intervention type Biological
Interventions GPI-0100, MUC-2-Globo H-KLH conjugate vaccine
Enrollment 34
Start date Jul 1, 2000
Primary completion Mar 1, 2009
Completion Mar 1, 2009
First posted Jan 27, 2003
Last update posted Mar 19, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies